Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 9,132 matching trials from the live ClinicalTrials.gov search.

Filters: Tampa, Florida Clear all

Conditions: Endometriosis
Interventions: Danazol Once Weekly, Danazol Twice Weekly, Placebo Once Weekly, Placebo Twice Weekly; Drug
Lead sponsor: Lumara Health, Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 38
States / cities: Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 30 more

Conditions: Malignant Pleural Mesothelioma
Interventions: CRS-207, Pembrolizumab; Biological
Lead sponsor: Aduro Biotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 8
States / cities: San Francisco, California • Tampa, Florida • Chicago, Illinois + 5 more

Conditions: COPD
Interventions: BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg, BGF MDI 160/14.4/9.6 μg, BFF MDI 320/9.6 μg; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 8,588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 318
States / cities: Andalusia, Alabama • Athens, Alabama • Birmingham, Alabama + 249 more

Conditions: HIV Infections, Influenza
Interventions: Cold-adapted live attenuated influenza vaccine (FluMist), Inactivated influenza vaccine (IAIV); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 5 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 59
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 42 more

Conditions: Solid Tumors, Head and Neck Cancer, Lung Cancer, UC (Urothelial Cancer)
Interventions: MEDI4736, INCB024360; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 13
States / cities: San Francisco, California • Denver, Colorado • Miami, Florida + 10 more

Conditions: Influenza
Interventions: Oseltamivir IV, Oseltamivir Oral; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 56
States / cities: Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 47 more

Conditions: Congenital Bleeding Disorder, Haemophilia A
Interventions: turoctocog alfa; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Up to 11 Years · Male only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 18
States / cities: Phoenix, Arizona • Orange, California • Torrance, California + 15 more

Conditions: Pain
Interventions: ZR-02-01 Fentanyl Transdermal Matrix Patch, Placebo Patch; Drug
Lead sponsor: ZARS Pharma Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 13
States / cities: Phoenix, Arizona • San Diego, California • Upland, California + 7 more

Conditions: Focal Seizures
Interventions: CBD-OS; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 24
States / cities: Phoenix, Arizona • La Jolla, California • New Haven, Connecticut + 20 more

Conditions: Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Durvalumab, Echocardiography Test, Iadademstat, Magnetic Resonance Imaging, Multigated Acquisition Scan; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 43
States / cities: Duarte, California • Irvine, California • La Jolla, California + 37 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Inhaled Human Insulin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 37
States / cities: Irvine, California • Long Beach, California • Los Angeles, California + 29 more

Conditions: Vitiligo
Interventions: ruxolitinib, Vehicle; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 44
States / cities: Hoover, Alabama • Gilbert, Arizona • Fountain Valley, California + 36 more

Conditions: Prostate Cancer, Prostate Adenocarcinoma, Biochemical Recurrence of Malignant Neoplasm of Prostate
Interventions: Copper Cu 64 PSMA I&T; Drug
Lead sponsor: Curium US LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 31
States / cities: Fullerton, California • Los Angeles, California • Newport Beach, California + 24 more

Conditions: Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
Interventions: Obrixtamig, ZL-1310, Atezolizumab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Lexington, Kentucky

Conditions: Hypertension
Interventions: metoprolol succinate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 16 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 30
States / cities: Little Rock, Arkansas • Bellflower, California • Beverly Hills, California + 27 more

Conditions: Advanced Non-Small Cell Lung Cancer
Interventions: fianlimab, cemiplimab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 23
States / cities: Tucson, Arizona • Yuma, Arizona • Redlands, California + 20 more

Conditions: Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease
Interventions: Infusion of one MPC expanded cord unit and one unexpanded cord unit, Infusion of two unexpanded cord blood units.; Biological
Lead sponsor: Mesoblast, Ltd.; Industry
Eligibility: Up to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 9
States / cities: Miami, Florida • Tampa, Florida • Boston, Massachusetts + 5 more

Conditions: Alzheimer's Disease
Interventions: Aducanumab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 1,027 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 130
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 107 more

Conditions: Melanoma
Interventions: Pembrolizumab/Vibostolimab, Pembrolizumab; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 12 Years and older
Enrollment: 1,594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 30
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 22 more

Conditions: Heart Transplant Rejection
Interventions: MMDx diagnostic test, Prospera, HLA antibody; Diagnostic Test
Lead sponsor: University of Alberta; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 6
States / cities: Little Rock, Arkansas • Tampa, Florida • West New York, New Jersey + 3 more

Conditions: Rheumatoid Arthritis
Interventions: AZD1163, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 29
States / cities: Glendale, Arizona • Prescott Valley, Arizona • Tucson, Arizona + 25 more

Conditions: Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS, Aggression
Interventions: IGC-AD1-Active, IGC-AD1-Placebo; Drug
Lead sponsor: IGC Pharma, LLC; Industry
Eligibility: 60 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 21
States / cities: Maitland, Florida • Melbourne, Florida • Miami, Florida + 15 more

Conditions: Hypertension
Interventions: nebivolol, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 75
States / cities: Gulf Shores, Alabama • Huntsville, Alabama • Mesa, Arizona + 63 more

Conditions: Diabetes Mellitus, Insulin-Dependent
Interventions: GlucoWatch® G2™ Biographer (GW2B), Continuous Glucose Monitoring System (CGMS); Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 7 Years to 17 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2004
U.S. locations: 6
States / cities: Stanford, California • Denver, Colorado • New Haven, Connecticut + 3 more

Search by objective public record fields.

Pain Associated With Endometriosis

Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents

A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza

Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A

Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Osteoarthritis (OA) Pain

A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy.

Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer

DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies

A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

Trifecta-Heart cfDNA-MMDx Study

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

Clinical Trial on Agitation in Alzheimer's Dementia

Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients

Randomized Clinical Trial to Assess the Effectiveness of the GlucoWatch Biographer